Press Secretary on Ohio’s Medicare Drug Price Negotiation Decision
TL/DR –
For decades, Big Pharma prevented Medicare from negotiating lower drug prices for seniors, leading to high healthcare costs for millions of families. The passing of the Inflation Reduction Act by President Biden and Congressional Democrats has allowed Medicare to negotiate lower prices for seniors’ medication. The program resulting from this act is anticipated to decrease prescription drug costs for millions of Americans suffering from common conditions such as heart failure, blood clots, diabetes, and arthritis.
Big Pharma’s Medicare Monopoly Overcome by President Biden’s Inflation Reduction Act
Big Pharma monopolized Medicare for years, dictating the price of drugs for seniors while reaping substantial profits. However, President Biden and the Congressional Democrats have recently disrupted this trend by passing the Inflation Reduction Act. Unfortunately, every Republican in Congress sided with Big Pharma, favoring high health care costs that burden millions of American families.
The recent Southern District of Ohio ruling strengthens Medicare’s capacity to negotiate lower drug prices for seniors. This ruling empowers the Biden-Harris Administration to continue advocating for affordable healthcare. They firmly believe that the Constitution doesn’t prohibit Medicare from negotiating drug prices.
Thanks to President Biden’s Inflation Reduction Act, millions of Medicare beneficiaries will experience a significant drop in prescription drug costs. The Act targets pricey drugs that treat widely prevalent conditions like heart failure, blood clots, diabetes, and arthritis.
President Biden emphasizes that Americans should not be forced to pay two to three times more for prescription drugs than their counterparts in other developed nations. Despite numerous obstacles from Republicans and Big Pharma, the Administration resolves to fight for more affordable healthcare for American families.
Read More US Economic News